

References

Chapter 29

- 1 Agency for Healthcare Research and Quality. Registries for Evaluating Patient Outcomes: A User's Guide, 2nd edn. Available from: <http://effectivehealthcare.ahrq.gov/ehc/products/74/531/Registries%20nd%20ed%20final%20to%20Eisenberg%209-15-10.pdf> (last accessed 18 November 2015).
- 2 Kennedy L, Craig AM. Global registries for measuring pharmaco-economic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation. *Pharmacoeconomics*. 2004;**22**(9):551–68.
- 3 Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response. *Nature Reviews Drug Discovery*. 2011;**10**(7):495–506.
- 4 Lauer MS, D'Agostino RB Sr. The randomized registry trial – the next disruptive technology in clinical research? *New England Journal of Medicine*. 2013;**369**(17):1579–81.
- 5 Lagerqvist B, Fröbert O, Olivecrona GK, Gudnason T, Maeng M, Alström P, et al. *New England Journal of Medicine*. 2014; 18;**371**(12):1111–20.
- 6 Multiple Sclerosis International Federation. Atlas of MS 2013: Mapping of Multiple Sclerosis around the World. Available from: <http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf> (last accessed 18 November 2015).
- 7 Piehl F. A changing treatment landscape for multiple sclerosis: challenges and opportunities. *Journal of Internal Medicine*. 2014;**275**(4):364–81.
- 8 Flachenecker P, Stuke K. National MS registries. *Journal of Neurology*. 2008;**255**(Suppl. 6):102–8.
- 9 Hurwitz BJ. Registry studies of long-term multiple sclerosis outcomes: description of key registries. *Neurology*. 2011;**76**(1 Suppl. 1):S3–6.
- 10 Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*. 1992;**55**(8):671–6.
- 11 Butzkueven H, Chapman J, Cristiano E, Grand' Maison F, Hoffmann M, Izquierdo G, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. *Multiple Sclerosis*. 2006;**12**(6):769–74.
- 12 Bronnum-Hansen H, Koch-Henriksen N, Stenager E. The Danish Multiple Sclerosis Registry. *Scandinavian Journal of Public Health*. 2011;**39**(7 Suppl.):62–4.
- 13 Myhr KM, Grytten N, Aarseth JH, Nyland H. The Norwegian Multiple Sclerosis National Competence Centre and National Multiple Sclerosis registry – a resource for clinical practice and research. *Acta Neurologica Scandinavica. Supplementum*. 2006;**183**:37–40.
- 14 Andersen O. From the Gothenburg cohort to the Swedish multiple sclerosis registry. *Acta Neurologica Scandinavica. Supplementum*. 2012;**195**:13–19.
- 15 Trojano M, Paolicelli D, Lepore V, Fuiani A, Di Monte E, Pellegrini F, et al.; Italian MSDN Group. Italian Multiple Sclerosis Database Network. *Neurological Science*. 2006;**27**(Suppl. 5):S358–61.
- 16 Stuke K, Flachenecker P, Zettl UK, Elias WG, Freidel M, Haas J, et al. Symptomatology of MS: results from the German MS Registry. *Journal of Neurology*. 2009;**256**(11):1932–5.
- 17 Fox RJ, Salter AR, Tyry T, Sun J, You X, Laforet G, et al. Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the North American research committee on multiple sclerosis database. *International Journal of Multiple Sclerosis Care*. 2013;**15**(4):194–201.

- 18 Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. *Neurology*. 2011;**77**(13):1246–52.
- 19 Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*. 2014;**85**(1):67–75.
- 20 Ionescu I, Frangoulis B, Vukusic S, Contafavreux C; for the EDMUS Group. EDMUS, an international, user-friendly and evolutive database for multiple sclerosis patients. Available from: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=137863&XNSPRACHE_ID=1&XNKONGRESS_ID=150&XNMASKEN_ID=900 (last accessed 18 November 2015).
- 21 MSBase Foundation website: www.msbase.org.
- 22 Jokubaitis VG, Spelman T, Lechner-Scott J, Barnett M, Shaw C, Vucic S, et al. The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. *PLoS ONE*. 2013;**8**(3):e59694.
- 23 Wong J, Gomes T, Mamdani M, Manno M, O'Connor PW. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. *Canadian Journal of Neurological Science*. 2011;**38**(3):429–33.
- 24 Sorensen PS, Koch-Henriksen N, Ravnborg M, Frederiksen JL, Jensen K, Heltberg A, et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. *Multiple Sclerosis*. 2006;**12**(3):253–64.
- 25 Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. *Annals of Neurology*. 2009;**66**(4):513–20.
- 26 Lebrun C, Debouverie M, Jeannin S, Pittion-Voyovitch S, Bayreuther C, Berthier F. Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France. *Multiple Sclerosis*. 2008;**14**(7):933–9.
- 27 von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. *New England Journal of Medicine*. 2003;**348**(1):68–72.
- 28 Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *New England Journal of Medicine*. 2006;**354**(9):899–910.
- 29 Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab. *Annals of the Rheumatic Diseases*. 2015;**74**(2):354–60.
- 30 Askling J, Baecklund E, Granath F, Geborek P, Ford M, Backlin C, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. *Annals of the Rheumatic Diseases*. 2009;**68**(5):648–53.
- 31 Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. *New England Journal of Medicine*. 2006;**354**(9):911–23.
- 32 The Tysabri Touch Prescribing Program. Available from: <http://www.tysabri.com/safety-with-tysabri.xml> (last accessed 18 November 2015).
- 33 European Medicines Agency. Tysabri – European Public Assessment Report. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000603/human_med_001119.jsp&mid=WC0b01ac058001d124 (last accessed 18 November 2015).
- 34 Yousry TA, Major EO, Ryschkeiwitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. *New England Journal of Medicine*. 2006;**354**(9):924–33.
- 35 Sacripanti C, Piccinni C, Puccini A, Poluzzi E, Montanaro N. Analyses of natalizumab prescriptions and discontinuations in multiple sclerosis patients of an Italian region. ISPE/EuroDURG Better Public Health Through Pharmacoepidemiology and Quality of Use of Medicine, 30 November–3 December 2011, Antwerp, Belgium.
- 36 Mancardi GL, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, et al. Natalizumab: a country-based surveillance program. *Neurological Science*. 2008;**29**(Suppl. 2):S235–7.
- 37 Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, et al. The pharmacovigilance program on natalizumab in Italy: 2 years of experience. *Neurological Science*. 2009;**30**(Suppl. 2):S163–5.
- 38 Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, et al. Three years of experience: the Italian registry and safety data update. *Neurological Science*. 2011;**31**(Suppl. 3):295–7.

- 39 Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. *Journal of Neurology, Neurosurgery and Psychiatry*. 2014;**85**(11):1190–7.
- 40 Holmen C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. *Multiple Sclerosis*. 2011;**17**(6):708–19.
- 41 EDMUS Study Group. TYSEDMUS Study. Available from: http://www.edmus.org/en/dl/tys/TYSEDMUS_Synopsis.pdf (last accessed 18 November 2015).
- 42 Committee for Medicinal Products for Human Use. Assessment Report: Tysabri. International Non-Proprietary Name: Natalizumab. Procedure No. EMEA/H/C/000603/III/0059/G. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000603/WC500148205.pdf (last accessed 18 November 2015).
- 43 Piccinni C, Sacripanti C, Poluzzi E, Motola D, Magro L, Moretti U, et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. *European Journal of Clinical Pharmacology*. 2010;**66**(2):199–206.
- 44 Piccinni C, Sacripanti C, Poluzzi E, De Ponti F. Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants. *Pharmacoepidemiology & Drug Safety*. 2013;**22**(4):443–5.
- 45 Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. *Seminars in Arthritis and Rheumatism*. 2006;**36**(3):182–8.
- 46 Neovius M, Simard JF, Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. *Annals of the Rheumatic Diseases*. 2011;**70**(4):624–9.
- 47 Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. *Health Technology Assessment*. 2006;**10**(42):iii–xiii, 1.
- 48 Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. *Current Opinions in Rheumatology*. 2008;**20**(2):138–44.
- 49 Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. *European Journal of Health Economics*. 2008;**8**(Suppl. 2):S61–86.
- 50 Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L. Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. *Biologics*. 2015;**9**:119–27.
- 51 Simard JF, Arkema EV, Sundstrom A, Geborek P, Saxne T, Baecklund E, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? *Rheumatology*. 2011;**50**(1):204–13.
- 52 Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. *Annals of the Rheumatic Diseases*. 2010;**69**(9):1596–602.
- 53 Askling J, Foreb CM, Geborek P, Jacobsson LT, van VR, Feltelius N, et al. Swedish registers to examine drug safety and clinical issues in RA. *Annals of the Rheumatic Diseases*. 2006;**65**(6):707–12.
- 54 Neovius M, Simard J, Sundstrom A, Jacobsson L, Geborek P, Saxne T, et al. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. *Annals of the Rheumatic Diseases*. 2011;**70**(3):516–19.
- 55 Wadström H, Eriksson J, Neovius M, Askling J. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)? *Scandinavian Journal of Rheumatology*. 2015;**44**(1):22–28.
- 56 Wettermark B, Hammar N, Foreb CM, Leimanis A, Otterblad OP, Bergman U, et al. The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. *Pharmacoepidemiology & Drug Safety*. 2007;**16**(7):726–35.
- 57 Cars T, Wettermark B, Malmstrom RE, Ekeving G, Vikstrom B, Bergman U, et al. Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods

- using anti-TNF therapy as model. *Basic Clinical Pharmacology & Toxicology*. 2013;**112**(6):392–400.
- 58 Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekblom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. *Annals of the Rheumatic Diseases*. 2005;**64**(10):1414–20.
- 59 Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. *Annals of the Rheumatic Diseases*. 2005;**64**(10):1421–6.
- 60 Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. *Arthritis and Rheumatism*. 2010;**62**(12):3776–82.
- 61 Simard JF, Neovius M, Askling J. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. *Arthritis and Rheumatism*. 2012;**64**(11):3502–10.
- 62 Neovius M, Sundstrom A, Simard J, Wettermark B, Cars T, Feltelius N, et al. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. *Scandinavian Journal of Rheumatology*. 2011;**40**(1):8–15.
- 63 Eriksson JK, Johansson K, Askling J, Neovius M. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed? *Annals of the Rheumatic Diseases*. 2015;**74**(4):648–54.
- 64 Neovius M, Simard JF, Klareskog L, Askling J. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. *Annals of the Rheumatic Diseases*. 2011;**70**(8):1407–14.
- 65 Scott DL, Ibrahim F, Farewell V, O’Keeffe AG, Walker D, Kelly C, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. *BMJ*. 2015;350:h1046.
- 66 Eriksson JK, Neovius M, Bratt J, Petersson IF, van Vollenhoven RF, Geborek P, et al. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial. *Journal of the American Medical Association Internal Medicine*. 2013;**173**(15):1407–14.
- 67 Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. *Annals of the Rheumatic Diseases*. 2015;**74**(6):1094–101.
- 68 van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. *Lancet*. 2012;**379**(9827):1712–20.
- 69 Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis and Rheumatism*. 2012;**64**(9):2824–35.
- 70 O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. *New England Journal of Medicine*. 2013;**369**(4):307–18.
- 71 Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. *Lancet*. 1999;**353**(9164):1568–73.
- 72 Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. *Arthritis and Rheumatism*. 2004;**50**(1):55–62.
- 73 Belge K, Brück J, Ghoreschi K. Advances in treating psoriasis. *F1000Prime Reports*. 2014;**6**:4. doi:10.12703/P6-4.
- 74 Ormerod AD, Augustin M, Baker C, Chosidow O, Cohen AD, Dam TN, et al. Challenges for synthesising data in a network of registries for systemic psoriasis therapies. *Dermatology*. 2012;**224**(3):236–43.

- 75 Nijsten T, Wakkee M. Psocare: Italy shows the way in postmarketing studies. *Dermatology*. 2008; **217**(4):362–4.
- 76 Italian Medicines Agency. Comunicato Stampa 169: Dichiarazioni Direttore Generale Aifa su uso illecito farmaci in dermatologia. Available from: <http://www.agenziafarmaco.gov.it/it/content/dichiarazioni-direttore-generale-aifa-su-uso-illecito-farmaci-dermatologia> (last accessed 18 November 2015).
- 77 Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. *Journal of Drugs in Dermatology*. 2012; **11**(10):1210–17.
- 78 Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. *Archives of Dermatology*. 2012; **148**(4):463–70.
- 79 Carretero G, Ferrandiz C, Dauden E, Vanaclocha SF, Gomez-Garcia FJ, Herrera-Ceballos E, et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry. *Journal of the European Academy of Dermatology and Venereology*. 2015; **29**(1):156–63.
- 80 Svedbom A, Dalen J, Mamolo C, Cappelleri JC, Petersson IF, Stahle M. Treatment patterns with topicals, traditional systemics and biologics in psoriasis – a Swedish database analysis. *Journal of the European Academy of Dermatology and Venereology*. 2015; **29**(2):215–23.
- 81 Ahlehoff O, Skov L, Gislason G, Gniadecki R, Iversen L, Bryld LE, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. *Journal of the European Academy of Dermatology and Venereology*. 2015; **29**(6):1128–34.
- 82 Gisondi P, Cazzaniga S, Chimenti S, Maccarone M, Picardo M, Girolomoni G, et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. *British Journal of Dermatology*. 2015; **172**(6):1613–20.
- 83 Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry (PSOLAR)). *Journal of the American Academy of Dermatology*. 2015; pii: S0190-9622(14)02102-1. doi: 10.1016/j.jaad.2014.10.025.
- 84 Augustin M, Glaeske G, Schafer I, Rustenbach SJ, Hoer A, Radtke MA. Processes of psoriasis health care in Germany – long-term analysis of data from the statutory health insurances. *Journal of the German Society of Dermatology*. 2012; **10**(9):648–55.
- 85 Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. *Journal of the American Academy of Dermatology*. 2014; **70**(5): 871–81.
- 86 Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. *Journal of the American Medical Association Dermatology*. 2013; **149**(10):1180–5.
- 87 Ragnarson TG, Hjortsberg C, Bjarnason A, Gniadecki R, Heikkila H, Jemec GB, et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. *Acta Dermato-Venereologica*. 2013; **93**(4):442–5.
- 88 Garcia-Doval I, Rustenbach SJ, Stern R, Dam TN, Cohen AD, Baker C, et al. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. *British Journal of Dermatology*. 2013; **169**(3):710–14.
- 89 Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. *Dermatology*. 2008; **217**(4):365–73.
- 90 Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, et al. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.

- Journal of the American Academy of Dermatology*. 2014;**70**(2):257–62.
- 91** Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. *British Journal of Dermatology*. 2010;**163**(4):807–16.
- 92** Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. *British Journal of Dermatology*. 2012;**167**(Suppl. 3):3–11.
- 93** Menting SP, van Lumig PP, de Vries AC, van den Reek JM, van der KD, de Jong EM, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. *Journal of the American Medical Association Dermatology*. 2014;**150**(2):130–6.
- 94** Askling J, Forede CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. *Arthritis and Rheumatism*. 2005;**52**(7):1986–92.